Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

MELBOURNE, Australia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a plan to acquire $100 million of Ethereum over the next 12 months. The asset purchase of Ethereum will enhance a multi-faceted corporate strategy of cryptocurrency exposure, pharmaceutical drug development and asset acquisition within the Company’s key focus area of biotechnology to improve human health and society. The strategic purchase of Ethereum provides a significant opportunity to diversify assets, realize potential value, address current cash flow needs of the Company during the pre-revenue stage and help to accelerate future revenue growth potential by investing into the Company’s core assets to commercialization, whilst also identifying new opportunities to expand its IP portfolio through acquisition.

Read more at globenewswire.com